medigraphic.com
ISSN 1025-0255 (Electronic)

2016, Number 2

<< Back Next >>

AMC 2016; 20 (2)

Malignant pleural mesothelioma with thrombotic and hemorrhagic phenomena

Armas PBA, García RME, Armas MK, Acosta PS, Aldana RI

Language: Spanish
References: 20
Page: 129-134
PDF size: 363.68 Kb.


ABSTRACT

Background: the frequency of thrombotic and hemorrhagic phenomena in malignant pleural mesothelioma. The presentation´s purpose is to deepen the causes and its relation to asbesto.
Objective: to know the causes of these phenomena in this malignant disease.
Development: a brief analysis of the last four treated and diagnosed cases which had the same complications is performed. Hypercoagulability of blood, Virchow´s triad and paraneoplastic manifestations in malignant tumors or Trousseau´s syndrome are mentioned. It is pointed out that the three main causes established are thrombocytosis, disseminated intravascular coagulation with the consumption of coagulation factors and platelets, and the endothelial cells of the vasoconstrictor endothelin-1 release. In addition, asbesto is not always related to malignant pleural mesothelioma.
Conclusions: it is insisted on the causes for understanding the origin of these complications like thrombocytosis, DIC, and vasoconstrictor endothelin-1. It is considered that this subject has not been tackled enough in national medical literature.


REFERENCES

  1. Ochoa Carrillo FJ, Chávez Mac-Gregor M. Green Renner D, Green Schneeweiss L. Síndrome paraneoplásico. Su asociación con el carcinoma pulmonar. Cir Ciruj. 2003;71(2):150-61.

  2. Pendleton RC, Rodgers GM. Thrombosis and antithrombotic therapy. En: Greer JP, Arber DA, Glader B, List AF, Means Jr. RT, Paraskevas F, et al, editors. Wintrobe´s Clinical Hematology. 13 ed. Philadelphia: Lippincott William & Wilkins; 2014. p. 1218-56.

  3. Burt BM, Cameron RB, Mollberg NM, Kosinski AS, Schipper PH, Shrager JB, et al. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. J. Thorac Cardiovasc Surg. 2014;148(1):30-5.

  4. Nojiri S, Gemba K, Aoe K, Kato K, Yamaguchi T, Sato T, et al. Survival and prognostic factors in malignant pleural mesothelioma: A retrospective study of 314 patients in the West part of Japan. Jpn J Clin Oncol. 2011;41:32-9.

  5. Mederos Curbelo ON. Mesotelioma pleural maligno mixto localizado y neuralgia intercos-tal. En: Mederos Curbelo ON, Adefna Pérez RL, Armas Pérez BA, Barrera Ortega JC, Canal Rabbasa PP, Cantero Ronquillo AH, et al, editores. Cirugía torácica. Comentarios de casos clínico-quirúrgicos. 1 ed. La Habana: Ecimed; 2012. p. 200-1.

  6. Kotova S, Wong RM, Camerun RB. New and emerging therapeutic options for malignant pleural mesothelioma: review for early clinical trials. Cancer Manag Res. 2015;7:51-63.

  7. Wong SF, Newland L, John T, White SC. Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report. J Med Case Rep. 2012;6:261-6.

  8. Cruz Rodríguez CL. Sistema Internacional de Unidades. En: Suardiaz Parera JH, Cruz Rodrí-guez CL, Colina Rodríguez A de J. editores. Laboratorio Clínico. 1 ed. La Habana: editorial Ciencias Médicas; 2004. p. 67-75.

  9. Muñoz Molina GM. Estado actual del tratamiento quirúrgico del mesotelioma pleural. Rev Patol Resp. 2015;28(supl.1):203-9.

  10. Rodgers GW, Means Jr RT. Trombocytosis and essential trombocythemia. En: Greer JP, Arber DA, Glader B, List AF, Means Jr. RT, Paraskevas F, et al, editors. Wintrobe´s Clinical Hematology. 13 ed. Philadelphia: Lippincott William & Wilkins; 2014. p. 1122-7.

  11. Marfil Rivera LJ. Enfermedades hemorrágicas por defectos de la fase plasmática y de la fibrinolísis. En: Jaime Pérez JC, Gómez Almaguer D, editores. Hematología. La sangre y sus enfermedades. 2 ed. México: Mc Graw Hill Educación; 2009. p. 169-77.

  12. Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631-7.

  13. Zahid I, Sharif S, Routledge T, Alavi A. What is the best way to diagnose and stage malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg. 2011;12:254-9.

  14. Arellano Orden E, Romero Falcón A, Martín Juan J, Ocaña Jurado M. Rodríguez Panadero F, Montes Worboys A. Small-particle size talc is associated with poor outcome and increased inflamation thoracoscopic pleurodesis. Respiration. 2013;86:201-9.

  15. Lucchi M, Picchi A, Ali G, Chella A, Guglielmi G, Cristaudo A, et al. Multimodality treatment of malignant pleural mesothelio-ma with or without immunotherapy: does it change anything. Interact Cardiovasc Thorac Surg. 2010;10(4):572-6.

  16. Gayosso Gómez LV, Salinas Silva LC, Zárraga Granados G, Ramírez Salazar EG, Ortiz Quintero B. MicroRNAs como herramienta potencial para el diagnóstico del mesotelioma pleural maligno. Neumol Cir Torax. 2013;72(2):175-81.

  17. Rodríguez Panadero F. Diagnosis and Treat-ment of Malignant Pleural Mesotheliom. Arch Bronconeumol [Internet]. Apr 2015 [cited 2015 Abr 12];51(4):[about 15 p.]. Available from: http://www.sciencedirect.com/science/article/pii/S1579212915000415

  18. IASLC y IMIG. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma. J Thorac Oncol. 2011;6:1304-12.

  19. Díaz García B, de Pablo Gafas A, Laporta Hernández R, López García-Gallo C. Enfermedades pleurales malignas. Medicine. 2006;4309-14.

  20. Datta A, Smith R, Fiorentino F, Treasure T. Surgery in the treatment of malignant pleu-ral mesothelioma: recruitment into trials should be the default position. Thorax. 2014;69:194-7.




2020     |     www.medigraphic.com